• Metoprolol Tartrate: Selectivity as a Translational Tool

  2026-09-03

  Metoprolol Tartrate offers more than a cardioselective pharmacology control. Its β1 preference provides a strategic way to separate cardiac signaling from β2/β3-dependent tissue responses, including hematopoietic recovery after transplantation.

• Isorhamnetin: Reliable Cellular Assay Design

  2026-09-03

  This scenario-based guide shows how Isorhamnetin (SKU N1358) can be incorporated into reproducible cell viability, oxidative stress, apoptosis, and signaling workflows. It translates concentration, solvent, storage, and interpretation evidence into practical decisions for biomedical laboratories.

• SU6656 Src tyrosine kinases inhibitor: Lab Guide

  2026-09-02

  This scenario-based guide explains how SU6656 Src tyrosine kinases inhibitor, SKU B5839, can be evaluated in proliferation, viability, megakaryocyte maturation, and radiotherapy-related assays. It emphasizes solvent control, endpoint selection, evidence boundaries, and practical product-selection criteria.

• RESTRICT-seq Maps Epigenetic Dependencies in SCC

  2026-09-02

  The RESTRICT-seq preprint presents a time-gated CRISPR screening strategy for separating early and late genetic requirements during squamous cell carcinoma resistance. Its central implication is that epigenetic dependencies may be state- and time-specific, providing a framework for more precise cancer biology research and follow-up pharmacological validation.

• Imipenem Workflows for Antibacterial Research

  2026-09-01

  Imipenem combines broad-spectrum antibacterial activity with a practical water-based workflow for bacterial susceptibility, phagocytosis, and sepsis animal model studies. Its potential extension into antimicrobial-releasing intracortical probes is promising but remains a hypothesis requiring spatially resolved validation.

• Reversine: Aurora Kinase Inhibitor Workflow

  2026-09-01

  Reversine is a research tool for probing Aurora kinase signaling pathway activity, mitotic control, cancer cell proliferation inhibition, and apoptosis-related phenotypes. This guide explains formulation, controls, and interpretation boundaries; it is intended for laboratory research only and not for diagnostic, therapeutic, or medical use.

• RNA Pol II Inhibition and Apoptotic Signaling

  2026-08-31

  Harper et al. show that RNA Pol II inhibition kills cells through an active apoptotic response triggered by loss of hypophosphorylated RNA Pol IIA, rather than through transcriptional collapse alone. The study reframes transcription-targeting drug mechanisms and provides a framework for separating polymerase degradation-dependent signaling from passive mRNA and protein depletion.

• MLN8237 (Alisertib) Research Workflows

  2026-08-31

  Build reproducible Aurora A inhibition studies with MLN8237 (Alisertib), from nanomolar cell assays to mechanistic apoptosis and tumor-model validation. This guide connects retinoblastoma findings with practical dosing, controls, storage, and troubleshooting decisions for cancer biology research.

• CTOP for Reliable μ-Opioid Assays

  2026-08-30

  CTOP (SKU B5135) provides a defined μ-opioid receptor antagonist peptide for separating receptor-mediated signaling from nonspecific effects in viability, proliferation, and neuropharmacology experiments. This scenario-based guide connects recent opioid-circuit findings with practical controls, peptide handling, assay compatibility, interpretation, and vendor-selection criteria.

• Reversine (A3760): Aurora Kinase Assay Guide

  2026-08-29

  Reversine (SKU A3760) is an Aurora kinase inhibitor for investigating mitotic regulation, cell-cycle control, and cancer cell proliferation inhibition in research models. This guide covers handling, assay setup, and QC boundaries; the compound is for scientific research only and should not be used for diagnostic or therapeutic applications.

• Protease Inhibitor Cocktail for DFCP1–ATGL Assays

  2026-08-28

  Learn how a Protease Inhibitor Cocktail can protect DFCP1–ATGL measurements without obscuring EDTA-sensitive biology. This guide presents an endpoint-specific strategy for lipid droplet, cell lysate, and tissue extract assays.

• RNA m6A in Plant–Virus Antagonism

  2026-08-28

  The reference study identifies RNA m6A modification as a dynamic battleground between Arabidopsis antiviral defense and cucumber mosaic virus. It shows that host methyltransferases mark viral RNA for ECT8-mediated destabilization, while the CMV 2b protein suppresses this response by disrupting the MTB–HAKAI methyltransferase machinery and altering global plant m6A patterns.

• Adipose–Neural Axis in Cardiac Arrhythmia

  2026-08-27

  Fan et al. developed a stem cell-based coculture model showing how epicardial adipocyte-derived leptin activates sympathetic neurons and drives NPY/Y1R-dependent electrical instability in cardiomyocytes. The study connects adipose, neural, and calcium-handling pathways and identifies experimentally testable intervention points for arrhythmia research.

• PARP7–STAT1/2 Signaling in EAE: Study Insights

  2026-08-27

  The 2025 Cell Reports study identifies PARP7 as a suppressor of type I interferon signaling that destabilizes STAT1 and STAT2 through ADP-ribosylation, ubiquitination, and p62-mediated autophagic degradation. Inhibition of PARP7 restored interferon pathway activity and reduced experimental autoimmune encephalomyelitis in mice, providing a mechanistic link between intracellular proteostasis and autoimmune neuroinflammation.

• Liproxstatin-1 Workflows for Ferroptosis Research

  2026-08-26

  Use Liproxstatin-1 as a pathway-focused rescue control to distinguish ferroptotic death from apoptosis and nonspecific oxidative injury. Its nanomolar activity, lipid-peroxidation readouts, GPX4-deficient models, and renal injury applications support a practical workflow from assay validation to translational study design.

8471 records 2/565 page Previous Next 12345 下5页 Last page